News stories about Bellicum Pharmaceuticals (NASDAQ:BLCM) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bellicum Pharmaceuticals earned a news impact score of 0.03 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.2554767415801 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year … – GlobeNewswire (press release) (globenewswire.com)
- Bellicum Bounces With Cancer Drug Data (msn.com)
- Bellicum Pharma (BLCM) Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501 (streetinsider.com)
- Bellicum Pharmaceuticals Earnings Outlook (finance.yahoo.com)
- Where Bellicum Pharmaceuticals Inc’s (NASDAQ:BLCM) Earnings Growth Stands Against Its Industry (finance.yahoo.com)
Several research analysts recently commented on the stock. Cantor Fitzgerald set a $10.00 price objective on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday. Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Wednesday, January 10th. SunTrust Banks reduced their price objective on shares of Bellicum Pharmaceuticals to $18.00 and set a “buy” rating for the company in a research note on Wednesday, January 31st. Wells Fargo & Co lowered shares of Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 price objective for the company. in a research note on Wednesday, January 31st. Finally, ValuEngine lowered shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $16.88.
In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $8.63, for a total transaction of $2,248,978.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 1,141,822 shares of company stock worth $9,475,583 in the last 90 days. 18.77% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Bellicum Pharmaceuticals (BLCM) Receives Media Sentiment Score of 0.03” was published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/14/bellicum-pharmaceuticals-blcm-receives-media-sentiment-score-of-0-03/2028636.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.